In 2023, China was the second largest product/technology exporter in the global biopharmaceutical pipeline, with 143 pipeline transactions, runner up only to the US.
In China’s biopharmaceutical industry, it’s widely accepted that innovation, international expansion, and commercialization are key strategies
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?